BRCA2 and neoplasm: Although PARP inhibitors are currently used to treat tumours with BRCA1/2-deficiencies28, the loss of BRCA1 or BRCA2 in cell lines did not sensitize to AZD7648 monotherapy (Supplementary Fig. 6A), prompting us to seek an alternative genetic background to explore the potential for a PARP inhibitor and AZD7648 combination.